ADMAライブシグナル | Getagraph.comで利益を最大化

売る 107767 min ago

@ $5.32

発行日: 15 2月 2024 @ 05:41

リターン: 24.08%

前回のシグナル: 2月 15 - 03:10

前回のシグナル: 買う

リターン: 0.90 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:48):

Stats
本日の出来高	336 346
平均出来高	2.52M
時価総額	1.53B
EPS	$0 ( 2024-02-28 )
次の収益日	( $0.0500 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-50.73
ATR14	$0.00500 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Kestenberg-messina Kaitlin M.	Buy	192 320	Common Stock
2024-04-01	Kestenberg-messina Kaitlin M.	Buy	300 328	Stock Option (right to buy)
2024-03-31	Kestenberg-messina Kaitlin M.	Sell	2 085	Common Stock
2024-03-31	Grossman Adam S	Sell	21 752	Common Stock
2024-04-01	Kestenberg-messina Kaitlin M.	Sell	0	Common Stock

INSIDER POWER
-15.55
Last 100 transactions
Buy: 7 559 578 \| Sell: 9 852 560

ボリューム相関

長: -0.04 (neutral)

短: 0.14 (neutral)

Signal:(47.405) Neutral

ADMA Biologics Inc 相関

10 最も正の相関
LWAC	0.924
PRTA	0.912
CAC	0.91
ZGNX	0.906
ADMS	0.903
CRSP	0.901
NERV	0.897
GNLN	0.894
VYNE	0.894
JFU	0.893

10 最も負の相関
GOODM	-0.901
SVAC	-0.878
THMA	-0.874
DTEA	-0.869
TLGT	-0.868
SBBP	-0.863
PETV	-0.861
RMRM	-0.86
NAII	-0.851
NRDS	-0.851

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ADMA Biologics Inc 相関 - 通貨/商品

-0.76
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

0.31
( neutral )

0.74
( moderate )

ADMA Biologics Inc 財務諸表

Annual	2023
収益:	$258.21M
総利益:	$88.22M (34.16 %)
EPS:	$-0.130

FY	2023
収益:	$258.21M
総利益:	$88.22M (34.16 %)
EPS:	$-0.130

FY	2022
収益:	$154.08M
総利益:	$35.27M (22.89 %)
EPS:	$-0.430

FY	2021
収益:	$80.94M
総利益:	$1.17M (1.45 %)
EPS:	$-0.832

Financial Reports:

No articles found.

ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.